首页> 美国卫生研究院文献>Clinical and Translational Allergy >Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose
【2h】

Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose

机译:在舌下免疫治疗中选择最佳剂量:反应指数300指数的基本原理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sublingual immunotherapy (SLIT) is an effective and well-tolerated method of treating allergic respiratory diseases associated with seasonal and perennial allergens. In contrast to the subcutaneous route, SLIT requires a much greater amount of antigen to achieve a clinical effect. Many studies have shown that SLIT involves a dose–response relationship, and therefore it is important to use a proven clinically effective dose from the onset of treatment, because low doses are ineffective and very high doses may increase the risk of side effects. A well-defined standardization of allergen content is also crucial to ensure consistent quality, potency and appropriate immunomodulatory action of the SLIT product. Several methods of measuring antigenicity are used by manufacturers of SLIT products, including the index of reactivity (IR), standardized quality tablet unit, and bioequivalent allergy unit. A large body of evidence has established the 300 IR dose of SLIT as offering optimal efficacy and tolerability for allergic rhinitis due to grass and birch pollen and HDM, and HDM-induced moderate, persistent allergic asthma. The 300 IR dose also offers consistency of dosing across a variety of different allergens, and is associated with higher rates of adherence and patient satisfaction. Studies in patients with grass pollen allergies showed that the 300 IR dose has a rapid onset of action, is effective in both adults and children in the short term and, when administered pre-coseasonally in the long term, and maintains the clinical benefit, even after cessation of treatment. In patients with HDM-associated AR and/or asthma, the 300 IR dose also demonstrated significant improvements in symptoms and quality of life, and significantly decreased use of symptomatic medication. The 300 IR dose is well tolerated, with adverse events generally being of mild or moderate severity, declining in frequency and severity over time and in the subsequent courses. We discuss herein the most important factors that affect the selection of the optimal dose of SLIT with natural allergens, and review the rationale and evidence supporting the use of the 300 IR dose.
机译:舌下免疫疗法(SLIT)是一种有效且耐受良好的方法,用于治疗与季节性和多年生过敏原相关的过敏性呼吸道疾病。与皮下途径相反,SLIT需要大量抗原才能达到临床效果。许多研究表明SLIT涉及剂量反应关系,因此从治疗开始就使用经过临床验证的有效剂量就很重要,因为低剂量无效,非常高的剂量可能增加发生副作用的风险。明确定义的过敏原含量标准化对于确保SLIT产品的一致质量,效力和适当的免疫调节作用也至关重要。 SLIT产品的制造商使用了几种测量抗原性的方法,包括反应指数(IR),标准化质量的片剂单位和生物等效过敏单位。大量证据表明,SLIT的300 IR剂量可为因草和桦树花粉和HDM以及HDM引起的中度持续性过敏性哮喘引起的过敏性鼻炎提供最佳疗效和耐受性。 300 IR剂量还可在多种不同的过敏原中提供一致的剂量,并具有更高的依从性和患者满意度。对草花粉过敏患者的研究表明,300 IR剂量起效迅速,短期内对成人和儿童均有效,并且长期进行季节前给药,即使在临床上仍可维持疗效,甚至停止治疗后。在具有HDM相关性AR和/或哮喘的患者中,300 IR剂量也显示出症状和生活质量的显着改善,并且对症药物的使用显着减少。 300 IR剂量具有良好的耐受性,不良事件一般为轻度或中度,随着时间的流逝,频率和严重性在随后的疗程中逐渐下降。我们在这里讨论影响选择具有自然过敏原的SLIT最佳剂量的最重要因素,并回顾支持使用300 IR剂量的原理和证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号